Lv2
160 积分 2023-11-21 加入
1152 DM001: A novel bispecific ADC targeting TROP2 and EGFR with potent anti-tumor efficacy in PDX models
2天前
已完结
A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 in subjects with inoperable locally advanced or metastatic solid tumors (301)
4个月前
已完结
Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease
4个月前
已完结
Necitumumab: First Global Approval
4个月前
已完结
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family
5个月前
已完结
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
7个月前
已完结
Structural Comparison of Fucosylated and Nonfucosylated Fc Fragments of Human Immunoglobulin G1
7个月前
已完结
Generating Bispecific Human IgG1 and IgG2 Antibodies from Any Antibody Pair
7个月前
已完结
Controlled Fab-arm exchange for the generation of stable bispecific IgG1
7个月前
已完结
998P A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC)
8个月前
已完结
皖公网安备34019202002308
